Monocyte Chemoattractant Protein–1 Blockade Inhibits Lung Cancer Tumor Growth by Altering Macrophage Phenotype and Activating CD8 + Cells
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The role of chemokines in the pathogenesis of lung cancer has been increasingly appreciated. Monocyte chemoattractant protein-1 (MCP-1, also known as CCL2) is secreted from tumor cells and associated tumor stromal cells. The blockade of CCL2, as mediated by neutralizing antibodies, was shown to reduce tumorigenesis in several solid tumors, but the role of CCL2 in lung cancer remains controversial, with evidence of both protumorigenic and antitumorigenic effects. We evaluated the effects and mechanisms of CCL2 blockade in several animal models of non-small-cell lung cancer (NSCLC). Anti-murine-CCL2 monoclonal antibodies were administered in syngeneic flank and orthotopic models of NSCLC. CCL2 blockade significantly slowed the growth of primary tumors in all models studied, and inhibited lung metastases in a model of spontaneous lung metastases of NSCLC. In contrast to expectations, no significant effect of treatment was evident in the number of tumor-associated macrophages recruited into the tumor after CCL2 blockade. However, a change occurred in the polarization of tumor-associated macrophages to a more antitumor phenotype after CCL2 blockade. This was associated with the activation of cytotoxic CD8(+) T lymphocytes (CTLs). The antitumor effects of CCL2 blockade were completely lost in CB-17 severe combined immunodeficient mice or after CD8 T-cell depletion. Our data from NSCLC models show that CCL2 blockade can inhibit the tumor growth of primary and metastatic disease. The mechanisms of CCL2 blockade include an alteration of the tumor macrophage phenotype and the activation of CTLs. Our work supports further evaluation of CCL2 blockade in thoracic malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 9×
“The phenotype of macrocytic MDSCs is similar to that of M2 TAMs.”
BackgroundInfluentialMonocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190
“Re-educating” tumor-associated macrophages by targeting NF-κB
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792 · cited 1×
“However, TAMs can be redirected from an M2 to a non-M2 phenotype, for example, by blocking NF-kB activity (40) or that of other macrophage-activating agents (34, 39), and enhanced antitumor activity may thus be achieved.”
BackgroundGuiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
Soria, G., Yaal-Hahoshen, N., Azenshtein, E., Shina, S., Leider-Trejo, L., Ryvo, L., Cohen-Hillel, E., Shtabsky, A., Ehrlich, M., Meshel, T., et al. (2008) · Cytokine · doi:10.1016/j.cyto.2008.08.002 · Cited by 92
Research works printed but not linked: 44
- 2006, Clin Cancer Res, 12, 4794, 10.1158/1078-0432.CCR-06-0944 · DOI
- 2007, Annu Rev Immunol, 25, 267, 10.1146/annurev.immunol.25.022106.141609 · DOI · Paper page
- 2004, Semin Cancer Biol, 14, 149, 10.1016/j.semcancer.2003.10.009 · DOI · Paper page
- 2007, Neoplasia, 9, 556, 10.1593/neo.07307 · DOI · Paper page
- 2008, Cancer Immunol Immunother, 57, 123, 10.1007/s00262-007-0336-x · DOI · Paper page
- 1997, Cancer Res, 57, 4849
- 2005, Blood, 106, 3322
- 2007, Immunol Lett, 113, 19, 10.1016/j.imlet.2007.07.004 · doi:10.1016/j.imlet.2007.07.004
- 2007, Cancer Res, 67, 9417, 10.1158/0008-5472.CAN-07-1286 · DOI · Paper page
- 2009, Neoplasia, 11, 228, 10.1593/neo.81282 · DOI · Paper page
- 2000, Cancer Immunol Immunother, 49, 63, 10.1007/s002620050603 · DOI
- 1998, Cancer Immunol Immunother, 47, 72, 10.1007/s002620050506 · DOI
- 2000, Cancer Res, 60, 7002
- 1997, J Exp Med, 185, 99, 10.1084/jem.185.1.99 · DOI · Paper page
- 2007, Hum Antibodies, 16, 117
- 1996, Cancer Res, 56, 21
- 2005, Cancer Res, 65, 8379, 10.1158/0008-5472.CAN-05-0920 · DOI
- 1994, Growth Factors, 11, 29, 10.3109/08977199409015049 · DOI · Paper page
- 2003, J Immunol, 171, 5051, 10.4049/jimmunol.171.10.5051 · DOI · Paper page
- 2010, Cancer Res, 70, 109
- 2006, Clin Cancer Res, 12, 214, 10.1158/1078-0432.CCR-05-1178 · DOI
- 2005, Clin Cancer Res, 11, 6713, 10.1158/1078-0432.CCR-05-0883 · DOI · Paper page
- 1998, J Exp Med, 187, 601, 10.1084/jem.187.4.601 · DOI · Paper page
- 2006, J Clin Invest, 116, 2132, 10.1172/JCI27648 · DOI · Paper page
- 2008, J Leukoc Biol, 84, 679, 10.1189/jlb.1107729 · DOI
- 2007, J Immunol, 179, 3332, 10.4049/jimmunol.179.5.3332 · DOI · Paper page
- 2008, J Immunol, 180, 2886, 10.4049/jimmunol.180.5.2886 · DOI
- 2001, J Immunol, 166, 6483, 10.4049/jimmunol.166.11.6483 · DOI · Paper page
- 2009, Cancer Res, 69, 1685, 10.1158/0008-5472.CAN-08-2164 · DOI · Paper page
- 2008, Immunol Rev, 222, 155, 10.1111/j.1600-065X.2008.00607.x · DOI · Paper page
- 2006, Neoplasia, 8, 578, 10.1593/neo.06280 · DOI · Paper page
- 2000, Blood, 96, 34, 10.1182/blood.V96.1.34 · DOI · Paper page
- 2002, J Lab Clin Med, 140, 320, 10.1067/mlc.2002.128317 · DOI · Paper page
- 2005, Cancer Res, 65, 11752, 10.1158/0008-5472.CAN-05-1658 · DOI · Paper page
- 2005, J Cancer Res Clin Oncol, 131, 453, 10.1007/s00432-004-0667-3 · DOI
- 2009, J Biol Chem, 284, 34342, 10.1074/jbc.M109.042671 · DOI · Paper page
- 2005, J Immunol, 175, 4583, 10.4049/jimmunol.175.7.4583 · DOI · Paper page
- 2007, Cancer Lett, 252, 86, 10.1016/j.canlet.2006.12.012 · DOI · Paper page
- 2007, Cancer Metastasis Rev, 26, 737, 10.1007/s10555-007-9087-6 · DOI
- 1999, Hum Cell, 12, 197
- 2005, Carcinogenesis, 26, 513
- 2008, J Cell Biochem, 104, 1587, 10.1002/jcb.21652 · DOI
- 2009, Cancer Sci, 100, 419, 10.1111/j.1349-7006.2008.01064.x · doi:10.1111/j.1349-7006.2008.01064.x
- 1997, Int J Cancer, 71, 257, 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D · doi:10.1002/(sici)1097-0215(19970410)71:2<257::aid-ijc22>3.0.co;2-d
Cited by
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Neutrophil plasticity in the tumor microenvironment
Giese, M. A., Hind, L. E., & Huttenlocher, A. (2019) · Blood · doi:10.1182/blood-2018-11-844548 · Cited by 783
Tumor entrained neutrophils inhibit seeding in the premetastatic lung
Granot, Z., Henke, E., Comen, E. A., King, T. A., Norton, L., & Benezra, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.012 · Cited by 782
More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis
Gschwandtner, M., Derler, R., & Midwood, K. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02759 · Cited by 611
Korbecki, J., Kojder, K., Simińska, D., Bohatyrewicz, R., Gutowska, I., Chlubek, D., & Baranowska-Bosiacka, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218412 · Cited by 465
Metadata
- Authors
- Fridlender, Z. G., Kapoor, V., Buchlis, G., Cheng, G., Sun, J., Wang, L.-C. S., Singhal, S., Snyder, L. A., & Albelda, S. M.
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02
- Volume
- 44
- Issue
- 2
- Pages
- 230-237
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- OpenAlex
- W2025767721
- Cited by
- 147
- References
- 5
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monocyte Chemoattractant Protein–1 Blockade Inhibits Lung Cancer Tumor Growth by Altering Macrophage Phenotype and Activating CD8 + Cells. https://app.cochat.ai/papers/10.1165/rcmb.2010-0080oc
- The paper
- Fridlender, Z. G., Kapoor, V., Buchlis, G., Cheng, G., Sun, J., Wang, L.-C. S., Singhal, S., Snyder, L. A., & Albelda, S. M. (2011). Monocyte Chemoattractant Protein–1 Blockade Inhibits Lung Cancer Tumor Growth by Altering Macrophage Phenotype and Activating CD8 + Cells. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2010-0080oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.